The proportion of medical insurance funds will increase the development space of innovative pharmaceutical enterprises

[pharmaceutical Station market analysis] at present, China's pharmaceutical innovation environment is good Many favorable policies, such as consistency evaluation of chemical generic drugs, priority evaluation of innovative drugs, and "4 + 7" volume procurement, encourage pharmaceutical enterprises to actively innovate and research, and promote the transformation of generic drugs to innovative drugs The industry believes that it is expected that in the next three years, the proportion of medical insurance funds obtained by innovative drugs in China will increase from 10% to 40%, which also means that there will be more space for innovative pharmaceutical enterprises to develop In addition, in the context of the rapid growth of innovative pharmaceutical enterprises, on April 30, 2018, the Hong Kong Stock Exchange allowed the IPO of biotechnology enterprises that have not yet achieved sales or have not yet made profits Many innovative pharmaceutical enterprises have submitted IPO applications to the Hong Kong stock exchange, which also indicates that the competition in the future innovative pharmaceutical market is increasingly fierce Among them, Geli pharmaceutical is the first innovative pharmaceutical enterprise to eat crabs after the new deal of the Hong Kong stock exchange After listing, the financing of enterprises for the secondary market provides more development space for Geli Facing 2019, Wu JINZI, President of Geli, said that it will implement the strategy of going to the global market; make original innovation and non-alcoholic fatty hepatitis drugs; in addition, it will also have more investment and innovation in the field of tumor due to the joining of Li Zhengqing Hualing Pharmaceutical Co., Ltd is the second innovative pharmaceutical company that has successfully IPO in Hong Kong, focusing on the field of diabetes From the perspective of the R & D layout of Hualing, the projects that have entered the clinical trials are all combined therapies around dorzagliatin, such as dorzagliatin + metformin, dorzagliatin + DPP-4, dorzagliatin + sglt-2, etc According to Hualing pharmaceutical, dorzagliatin (hms5552) is expected to complete clinical phase III by mid-2020, and then submit an application for drug marketing license Baiji Shenzhou is the first Chinese innovative drug company to be listed on NASDAQ and HKEx at the same time Among them, the products to be launched are the PD-1 drug tirelizumab, Btk inhibitor zambutinib, etc After IPO in Hong Kong, Xinda biology has made outstanding performance with pipeline changes of rate, fast pace and rich product line According to the financial report released by the company on March 14, 2019, the company invested 1.222 billion yuan in R & D in 2018, with as many as 20 projects entering clinical practice In addition to the PD-1 drug sindilimab, there are two biological analogues adamumumab and bevacizumab that have been submitted to NDA In addition, on the basis of cooperation with Lilly, Cinda biology has rapidly promoted BD after its listing It has not only established cooperation with domestic innovative drug enterprises and yellow medicine (PD-1 + furaquinidine) and micro core Biology (PD-1 + sidabamine), but also reached strategic cooperation with foreign enterprises such as Incyte Cornerstone pharmaceutical has accelerated its growth after submitting its IPO application According to the financial report, in 2018, the company invested RMB 850 million in R & D, and has established a strong pipeline composed of 14 tumor candidate drugs, including 3 key candidate drugs in clinical stage of tumor immunotherapy In addition, the cornerstone pharmaceutical industry is also digging for talents For example, Dr Xie Yizhao, executive director of cancer early clinical research and development department from moshadong, served as vice president and translational medicine officer of clinical development department, and hired three internationally renowned oncology experts as members of the Scientific Advisory Committee Innovative drugs have high barriers to competition, pricing power and huge demand space Once the new drugs are listed successfully, the performance of pharmaceutical companies is expected to enter a new height The industry said that although the science and technology innovation board ignited enthusiasm for biomedical enterprises, the pace of biotechnology enterprises disclosed by the Hong Kong Stock Exchange began to slow down, so innovative pharmaceutical enterprises also need to strengthen the core competitiveness.